Quick jump to page content
Main Navigation
Main Content
Sidebar
Register
Login
Toggle navigation
Home
About
About the Journal
Submissions
Editorial Team
Privacy Statement
Contact
Current
Archives
Submission
Search
Search
Search articles for
Advanced filters
Published After
2017
2018
2019
2020
2021
2022
2023
2024
January
February
March
April
May
June
July
August
September
October
November
December
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Published Before
2017
2018
2019
2020
2021
2022
2023
2024
January
February
March
April
May
June
July
August
September
October
November
December
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
By Author
Search Results
Early and Maintained Response Levels in Psoriasis Patients Treated with Tildrakizumab
Kim A Papp, Jensen Yeung, Neil Shear, Lorne Albrecht, Charles Lynde, Jingchuan Zhang, Yang Zhao, Jeff Parno, Alan M Mendelsohn, Melinda Gooderham
Page s41
Poster PDF
Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2
Richard G Langley, Jeffrey Crowley, Melinda Gooderham, Kim A Papp, Neil J Korman, Lynda Spelman, Atsuyuki Igarashi, Mamitaro Ohtsuki, Aditya K Gupta, Paul Yamauchi, Jeffrey Parno, Alan M Mendelsohn, Stephen J Rozzo, Kimberly Eads
Page s39
Poster PDF
Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis
Boni Elewski, Alan Menter, Jeffrey Crowley, Stephen Tyring, Yang Zhao, Simon Lowry, Stephen Rozzo, Alan Mendelsohn, Jeffrey Parno, Kenneth Gordon
Page S22
Poster PDF
Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies
Kim Papp, Kristian Reich, Andrew Blauvelt, Diamant Thaci, Rodney Sinclair, Stephen K Tyring, Nicole Cichanowitz, Stuart Green, Qing Li, Carmen La Rosa
Page S4
Poster PDF
Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis
Neal Bhatia, J Gabriel Vasquez, Brad Schenkel, Jayme Heim
Page s134
Poster PDF
Patients’ quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis
Jayme Heim, J Gabriel Vasquez, Brad Schenkel, Neal Bhatia
Page s135
Poster PDF
Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2
Alan M Menter, Zoe Draelos, Jayme Heim, Ranga Gogineni, Christopher EM Griffiths
Page s136
Poster PDF
Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies
Mark G Lebwohl, Nehal N Mehta, Alice B Gottlieb, Alan M Mendelsohn
Page s42
Poster PDF
Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in Resurface 1
Wendy Cantrell, Patricia Lee, Alan M Mendelsohn, Jeff Parno, Stephen J Rozzo, Wilson Liao
Page s40
Poster PDF
1 - 9 of 9 items
×
Modal Header